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    Abstract 
 
Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused 
by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a 
significant antibody response for some CLL patients. In this study we investigated 
antibody persistence after PCV7 in patients with CLL. The study material comprised 24 
patients with CLL and 8 immunocompetent controls.  The median antibody concentrations 
five years after PCV7 were lower for six pneumococcal serotypes in patients with CLL 
compared to controls, but the difference was not statistically significant. Depending on the 
serotype, the percentage of the CLL patients with antibody levels suggested to provide 
protection against invasive pneumococcal disease (IPD) varied from 29 to 71% five years 
after vaccination. This data suggests that PCV could result in antibody persistence at least 
five years in CLL patients. 
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Chronic lymphocytic leukemia (CLL), a mature B-cell neoplasm, is the most common type 
of leukemia in adult Caucasians.1 CLL is associated with a significant dysfunction of the 
immune system that results in both quantitative and qualitative defects in innate and 
adaptive immune responses.2 While hypogammaglobulinemia can occur even in the early 
stage of disease, it usually becomes more severe during the course of the disease and at 
more advanced stages.3 Infections are the most common cause of mortality in CLL 
patients. The majority of infections are bacterial, caused by common organisms, including 
Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae.4 
 
Previous studies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in 
patients with CLL demonstrated no antibody responses at all or only weak responses.5-8 In 
contrast, the immunogenicity of pneumococcal conjugate vaccine (PCV) in patients with 
CLL has been shown in a few earlier studies. A single dose of 7-valent pneumococcal 
conjugate vaccine (PCV7) given at an early stage of the CLL resulted in a significant 
response in almost 40% of patients.9 Furthermore, 13-valent pneumococcal conjugate 
vaccine (PCV13) induced at least a two-fold increase in antibody titers from baseline in 58% 
of previously untreated CLL patients, but an antibody concentration of 0.35 μg/ml was not 
used as a serological threshold for adequate response.10 Many current international 
guidelines recommend PCV13 for immunocompromised patients. The persistence of 
pneumococcal antibodies in patients with CLL has yet to be studied. 
 
In this follow-up study, pneumococcal antibody persistence was assessed in CLL patients   
and immunocompetent controls at five years after one dose of PCV7 given as part of an 
earlier response study.9 
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The study population comprised 24 patients with CLL (12 males and 12 females), with a 
median age of 64 years (range 47-86 years) from Tampere and Turku University Hospitals. 
The control population comprised 8 subjects (median age 67 years, range 57-82 years, 4 
males and 4 females) without any known immunological or hematological defects from 
Tampere University Hospital. The patients and control subjects had participated in an 
earlier pneumococcal vaccine response study with PCV7.9 
 
An informed consent to participate was obtained from all patients and controls. The study 
was approved by the ethical board of the Pirkanmaa Hospital District and the trial was 
registered at http://ClinicalTrials.gov (NCT00919321). 
 
Clinical and laboratory characteristics of the CLL patients are shown in Table 1. The 
disease status according to Binet classification was A (early stage of the disease) in 16, B 
(intermediate) in 2, and C (advanced stage) in 6 patients. A total of 16 patients had never 
been treated for CLL. Seven patients had suffered from severe infections (needing 
intravenous antibiotics or hospitalization) and six patients from mild to moderate infections 
(treated with oral antibiotics) during the five years since PCV7 vaccination. Only one of 
these infections was pneumococcal infection, i.e. pneumococcal septicemia.  
Hypogammaglobulinemia (S-IgG <6.77 g/l) was detected in 11 patients. The 
concentrations of serum IgG antibody against pneumococcal capsular polysaccharides 
were measured by a modification of the 22F inhibition enzyme immunoassay (EIA) 
method as previously described.11 An antibody concentration of 0.35 μg/ml was considered 
as a threshold for protection against invasive pneumococcal disease (IPD), as 
recommended by World Health Organization WHO.12 A comparison of antibody 
concentrations between CLL patients and controls was performed with Fisher´s exact test. 
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Pneumococcal antibody concentrations four weeks and five years after the administration 
of PCV7 are shown in Table 2. In the CLL patients, median antibody concentrations 
against pneumococcal serotypes 4, 6B, 18C and 19F after five years were approximately 
50% lower than those measured four weeks after vaccination. Furthermore, antibody 
concentrations against serotypes 9V and 23F were approximately 75% and 65% lower five 
years after vaccination, respectively. In contrast, the median concentration of the antibody 
against serotype 14 remained at a similar level over the five-year period following the 
vaccination. No statistically significant differences were seen in antibody concentrations 
between CLL patients and controls five years from vaccination.  The pneumococcal 
antibody concentrations in controls declined by more than 50 % in each serotype group. 
The median concentration of the antibody against serotype 9V was 95% lower in controls, 
as measured five years after the administration of PCV7.  
 
The percentages of subjects whose antibody concentrations were at a level suggested to be 
protective against IPD five years after the administration of PCV7 are shown in Figure 1. 
In patients with CLL, these percentages varied from 29 to 71%, with the lowest proportion 
found against serotype 4 and the highest against serotypes 18C and 19F. In controls, the 
corresponding percentages ranged 50- to 87.5%, with the lowest proportion being against 
serotype 6B and the highest against serotype 18C. 
 
The baseline proportions of suggested protective antibody concentrations before 
vaccination in patients with CLL ranged 8- to 88%. The lowest baseline proportion was 
against serotype 4 and the highest against serotype 19F. In controls, the same percentages 
were 0-100%, with no protective concentrations found against serotype 4. Protective 
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antibody concentrations against serotype 18C were observed in all controls before 
vaccination.9 
 
There is no earlier data available concerning pneumococcal antibody persistence in patients 
with CLL. In HIV-infected children on HAART, protective antibody concentrations of 
≥0.5 μg/ml persisted for longer than four years for serotypes 6B and 14 after PCV7-PCV7-
PPV23 administration.13 In adults of 50 years of age and older, antibody concentrations 
declined over a five-year period following the administration of PCV13 for all 13 serotypes 
but remained higher than the levels before vaccination, except for serotype 3.14 
Furthermore, in 40% of allogeneic stem cell transplant patients, who received three doses 
of PCV7 and one dose of PPV23 after transplantation, antibody concentrations remained at 
a protective level (≥0.50 μg/ml) for 8-11 years.15  
 
In our data antibody concentrations in patients with CLL declined during the five years 
following a single dose of PCV7 for six serotypes and for all serotypes in healthy controls. 
The number of subjects was quite small, but no statistically significant difference was seen 
between these two groups in median antibody concentrations. There was, however, a trend 
toward lower antibody concentrations in CLL patients compared to controls five years after 
PCV7 administration for all serotypes except for serotype 19F, which was observed in 
higher concentrations in the patients. Currently recommended PCV13 contains six other 
serotypes (1, 3, 5, 6A, 7F, 19A), which are not included in PCV7. Antibody persistence in 
these additional serotypes remains still unclear and warrants further studies. 
 
More than half of the CLL patients remained their antibody concentrations at protective 
levels for four out of seven serotypes five years after PCV administration, although the 
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median antibody concentrations declined. Most of the patients had never been treated for 
CLL, which may have some impact on antibody persistence. Also, the relatively low rates 
of hypogammaglobulinemia and the low number of severe pneumococcal infections may 
contribute to better persistence of protection. Although the size of the study population was 
small, this follow-up data reflects the trend of the antibody persistence five years after 
PCV7 in patients with CLL. 
 
Earlier data had shown a significant increase in antibody concentrations for all seven 
antigens in both groups after PCV7 administration.9 In this follow-up study, the median 
antibody concentrations in CLL patients at five years after vaccination, as compared with 
the baseline levels before vaccination, varied depending on the serotype. The post-
vaccination antibody concentrations for serotypes 4 and 14 were 1.6- and 1.3 –times higher 
than the baseline, respectively. In contrast, for serotypes 6B and 18C, the median antibody 
concentrations declined by almost 20% during the five-year follow-up. Antibody 
concentrations for the other three serotypes declined to baseline levels. Whether antibody 
concentrations continue to decline after five years of follow-up remains unclear and 
warrants a longer follow-up and further studies.  
 
In our earlier data, serotypes 14 and 6B were the most common serotypes causing IPD 
among patients with hematological malignancy, including CLL. Our finding of favorable 
persistence for serotype 14 emphasizes the importance of PCV administration for CLL 
patients in the early stages of the disease, whereas the decline below baseline seen for 
serotype 6B during the follow-up period may point to a need for a booster dose of PCV or 
PSV five years after the primary vaccination. 
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In conclusion, median antibody concentrations in patients with CLL five years after PCV7 
administration varied depending on the serotype as compared to controls, and there was a 
trend toward lower antibody concentrations for six serotypes of PCV7. However, antibody 
concentrations remained at a level considered to be protective against IPD for four 
serotypes in more than 50% of the CLL patients. Our findings suggest that PCV given at an 
early stage of CLL could result in antibody persistence lasting at least five years. The 
effectiveness and schedule of possible booster immunization needs to be established in 
future studies. 
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Figure 1. The proportions of antibody concentrations suggestive of protection (≥0.35 μg/ml) 
against pneumococcal antigens of 7-valent pneumococcal conjugate vaccine in patients with 
CLL and in controls five years after vaccine administration. 
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Table 1. Clinical and laboratory characteristics of the patients with CLL. 
 
Character Patients with CLL (N=24) 
Sex M/F 12/12 
Age (years) 64 (47-86) 
Binet A/B/C 16/2/6 
Past or ongoing therapy 8 (33%) 
Lymphocyte count (x109/l) 24.3 (0.9-140.0) 
Platelet count (x109/l) 141 (38-372) 
Hemoglobin (g/l) 135 (81-153) 
Neutrophil count (x109/l 4.0 (0.6-12.1) 
IgG (g/l) 7.4 (3.2-12.5) 
IgM (g/l) 0.3 (0.1-5.4) 
IgA (g/l) 0.7 (0.2-4.5) 
 
 
 
 
 
 
 
Table 2. Antibody concentrations against pneumococcal antigens of 7-valent conjugate vaccine 
four weeks and five years after vaccination in patients with CLL and in controls. 
 
Serotype Post-PCV antibody 
level median (quartiles) 
 
CLL                       Control    
                       
5 yrs post-PCV antibody                         P-value1         
level median (quartiles) 
 
CLL                      Control 
4 0.30 (0.07-1.22)    1.87 (0.43-6.16) 0.15 (0.02-0.40)    0.52 (0.13-0.90)         0.116 
6B 0.55 (0.20-1.82)    0.95 (0.23-14.7) 0.29 (0.09-0.94)    0.39 (0.06-1.24)         1.000 
9V 1.40 (0.25-7.12)    18.0 (0.34-63.2) 0.33 (0.15-2.33)    0.97 (0.17-5.06)         0.685 
14 0.72 (0.31-2.66)    14.7 (1.01-20.5) 0.73 (0.20-4.01)    2.71 (0.45-5.83)         0.676 
18C 1.55 (0.81-5.99)    9.76 (4.65-81.1) 0.73 (0.23-3.06)    1.42 (1.00-2.47)         0.642 
19F 2.01 (0.61-9.31)    3.26 (1.20-51.1) 1.07 (0.26-2.88)    0.69 (0.31-1.56)         1.000 
23F 1.53 (0.66-13.4)    5.11 (0.98-23.0) 0.51 (0.17-1.56)    1.17 (0.11-2.23)         1.000 
1Fisher´s exact test. 
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